












Background: Young cancer patients may occasionally face infertility and premature gonadal failure. Apart from its
direct effect on follicles and oocytes, chemotherapy may induce ovarian toxicity via an impact on the entire ovary.
The role of doxorubicin in potential ovarian failure remains obscure. Our intention was to elucidate doxorubicin-
related toxicity within ovaries.
Methods: Female mice were injected intraperitoneally with 7.5 or 10 mg/kg doxorubicin and their ovaries were
visualized in vivo by high resolution MRI, one day and one month following treatment. Ovaries of other treated
mice were excised and weighed at the same post-treatment intervals. Ovarian histological sections were stained
for TUNEL or active caspase-3 and follicles were counted and categorized. Ovulation rates were evaluated in
superovulated female mice treated with doxorubicin.
Results: A single injection of doxorubicin resulted in a major reduction in both ovarian size and weight that lasted
even one month post treatment. A dramatic reduction in ovulation rate was observed one week after treatment,
followed by a partial recovery at one month. Histological examination revealed positive staining of TUNEL and
active caspase-3. We observed a significant reduction in the population of secondary and primordial follicles one
month following treatment.
Conclusions: Our results may imply a mechanism of chemotherapy-induced ovarian toxicity, manifested by
reduced ovulation and accompanied by a reduction in ovarian size, caused probably by an acute insult to the
ovary.
Background
Recent advances in cancer therapy have improved the
long-term survival of young cancer patients who then
may face iatrogenic infertility and premature gonadal
failure [1]. Although the need for tumor eradication in
these patients is clear, the long-term effects of che-
motherapy, observed on non-target tissues such as ovar-
ies, are substantial and raise concern and potential
health risks in women surviving diseases as breast can-
cer, Hodgkin’s disease and leukemia. The assessment of
chemotherapy-induced gonadal toxicity is based mainly
on indirect parameters as menstrual history, incidence
of amenorrhea, hormones levels and surveys of subse-
quent parity [1-4]. Former studies had demonstrated
apoptotic changes in the pregranulosa cells that result in
follicular damage [5,6], injury to blood vessels and focal
ovarian cortical fibrosis [7] following cyclophosphamide
administration. The outcome of ovarian damage due to
chemotherapy depends on the size of the follicular
reserve, which is age-related [1]. According to these stu-
dies, chemotherapy may affect the entire ovary aside
from the direct effect it exerts on the follicles and
oocytes. Alkylating agents play a role in inducing prema-
ture ovarian failure [5,8,9]. Though it has been demon-
strated that doxorubicin, an anthracycline agent, arouses
apoptosis in oocytes, the role of anthracyclines in indu-
cing ovarian failure remains obscure [6,10,11]. The risk
of developing amenorrhea following treatment with dox-
orubicin-containing protocols ranges from 20% to 80%,
depending on the woman’s age (high incidence at the
age of 40 and older; moderate incidence at the age of
30-39; 1,4). The pattern of chemotherapy-induced ovar-
ian injury may consist of endovascular damage since
signs of fibrosis in the cortical stroma and changes in
the capillaries were observed [7,12]. Analogous pattern
was presented also in biopsies retrieved from patients
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motherapeutic regimens [13].
I nt h ec u r r e n ts t u d yw eh a v ee s t a b l i s h e dap l a t f o r m
of in vivo imaging for investigating the short and long
term effects of doxorubicin on the ovaries. We have
characterized the pattern of mice ovarian toxicity,
induced following an in vivo administration of doxoru-
bicin. First, we characterized the mode of tissue
impairment, by assessing the pattern of apoptosis
within the affected ovary. We then followed the modi-
fications in ovarian function, demonstrated by an
altered ovulation rate. A sharp decline in ovary size
was observed by in vivo imaging, verified by a corre-
sponding decline in ovarian weight. Our results may
indicate a mechanism of chemotherapy-induced ovar-
ian toxicity, manifested by reduced ovulation and
accompanied by a reductioni no v a r i a ns i z ed u et o
possible acute ovarian insult.
Methods
I C Rf e m a l em i c e( 7 - 8w e e k sold; Harlan Laboratories,
Jerusalem, Israel) were housed in air conditioned, light
controlled animal facilities of the Sackler faculty of
Medicine in Tel-Aviv University. Animal care was in
accordance with institutional guidelines and was
approved by the local authorities. Doxorubicin (Teva;
Petach-Tikvah, Israel) and saline were injected at a
volume of 100 μl/10 gr body weight.
Ovary weight
Four weeks old immature ICR female mice were
injected intraperitoneally (IP) with either 7.5 mg/kg
doxorubicin in saline or with saline alone (control) and
their ovaries were excised and weighed one week or
one month later. The ovaries of 4-weeks old females
are comprised mostly of follicles, without corpora
lutea.
Ovulation rate
We studied the effect of a single injection of doxorubi-
cin (10 mg/kg) on ovulation rate in 7-8 weeks old ICR
female mice. Control mice were injected IP with saline.
Ovulation was induced by injecting the mice with 5 IU
human chorionic gonadotropin (hCG; Sigma, St Louis,
MO, USA) 48 hours after administration of 10 IU preg-
nant mare serum gonadotropin (PMSG; Syncro-part,
S a n o f i ,P a r i s ,F r a n c e ) .T h em i c ew e r es a c r i f i c e d1 6 - 1 7
hours after hCG administration at a time coinciding
with either 48 hours, one week or one month after the
doxorubicin or saline injection. Ovulated oocytes were
isolated from the oviductal ampullae into Toyoda
HEPES (TH) medium [14] supplemented with 0.4% BSA
(fraction V, Sigma) and counted.
High resolution magnetic resonance imaging (MRI) for
measuring ovarian size
Female mice, 7-8 weeks old were injected IP with 7.5
mg/kg doxorubicin (n = 9) or with saline (n = 9) and
subjected to MRI imaging of their ovaries. In order to
avoid the inter-individual variability, the same mice
were anesthetized before the injection (baseline) as well
as 1 day and 1 month after the injection, for repeated
imaging of their ovaries. Changes in ovary size and in
amount of fluids in the peri-ovarian bursal sac were
recorded.
Mice were anesthetized with isoflurane, (5% in oxygen
for induction, 1-3% for maintenance) at a rate of 1 liter/
min. Once anesthetized, the mice were installed in a
head-holder to assure a fixed positioning inside the
probe throughout the entire measurement period.
Respiration rate was monitored (60-80 breaths/min)
throughout the experimental period.
MRI experiments were performed using the 7 Tesla
BioSpec Magnet 70/30 USR system (Bruker, Germany)
equipped with a gradient coil system capable of produ-
cing pulse gradient of up to 40 gauss/cm in each of the
three directions. The MRI protocol included coronal
T2-weighted images that were acquired using the RARE
sequence, 256 × 128 matrix (interpolated to 256 × 256),
RARE factor of 8, and four averages, corresponding to
an image acquisition time of 3 min 44 sec. Twenty four
continuous slices of 0.85 mm thickness were acquired
with a field of view (FOV) of 6 cm × 6 cm.
The ovary volume was calculated from the T2-
weighted MR images using the Medical Image Analysis
(MIA version 2.4), MATLAB® image processing toolbox.
Apoptosis within ovaries
Four weeks old mice were excised 12 or 24 hours after
administration of 10 mg/kg doxorubicin or saline, fixed
in 4% paraformaldehyde, paraffinized and sectioned.
Immunohistochemistry was performed on deparaffinized,
paraformaldehyde-fixed sections of the excised mice
ovaries: TUNEL assay Roche-Applied-Science) for detec-
tion of DNA fragmentation and caspase-3 assay for
detection of apoptosis. Caspase-3 assay was performed
using an anti-caspase 3 antibody (cleaved caspase-3; Cell
Signaling Technology, MA, USA) according to Asheri-
Padan et al. [15]. Labeled sections were visualized and
photographed by a confocal laser-scanning microscope
(Leica TCS SP5; Mannheim, Germany), equipped with an
argon-ion laser (458 nm, 476 nm, 488 nm, 496 nm, 514
nm lines), a diode-pumped solid state laser (516 nm line)
and an UV diode laser. Water-immersion lenses (20×
NA/0.7 and 63× NA/1.2) were used for all imaging. The
sections were scanned using the confocal laser-scanning
microscopy program (Leica microsystem LAS AF).
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Four weeks old mice were injected IP with 7.5 mg/kg
doxorubicin, their ovaries excised one month later, fixed
in Bouin’s solution, embedded in paraffin, sectioned (6
μm) and mounted on Superfrost/Plus slides (Daigger
and Co., Wheeling, IL, USA). The Bouin-fixed ovarian
sections were stained with Hematoxylin-Eosin to detect
doxorubicin-induced variations in structure and number
of follicles. All ovarian follicles of every fifth consecutive
histological section were classified according to type and
counted. The numbers were multiplied by 5 to reach a
value representative of the total number of follicles
within an ovary as formerly described [16].
Statistical analysis
Each experiment was repeated at least three times. SPSS
10.0 software was used for statistical analysis. Two-way
analysis of variance (ANOVA) test was employed for
assessing the degree of correlation between counted folli-
cles of ovaries from treated and control groups. ANOVA
with repeated measures was used for assessing differences
in ovulation rate, ovarian weight and size (as measured
with MRI), between treated and control mice. Results
were considered statistically significant at P < 0.05.
Results
The effect of in vivo doxorubicin administration on
ovarian weight
The weights of ovaries excised from female mice either
one week or one month after injection of doxorubicin
were compared to weights of ovaries excised from sal-
ine-injected control mice at the same post-injection
time intervals. A time-dependant relative decrease in
ovarian weights was detected: from 85% of control value
at one week after treatment to 52% of control value one
month post treatment (P < 0.05; Fig. 1).
The effect of in vivo doxorubicin administration on
ovulation rate
Doxorubicin-treated female mice were injected with
PMSG and hCG to induce superovulation. Ovulation
rate was decreased from about half of control value at
48 hours to 4% at 1 week and recovered back to 52%
one month after treatment (Fig 2).
In vivo imaging of ovaries after doxorubicin treatment
The use of high-resolution MRI enabled live imaging of
mice ovaries with repeated monitoring of the same indi-
viduals thus minimizing variability. Post-treatment
changes in the size of mice ovaries at various time inter-
vals were tracked by this imaging platform. Since ovaries
of rodents are enclosed in a periovarian sac, the bursa,
we measured dimensions of both bursa and ovary in an
attempt to follow possible variations in size occurring as
a result of doxorubicin treatment. A continuous reduc-
tion in the size of ovaries over time (Fig 3A), with
fluctuations in bursal dimensions were observed.,
A peri-ovarian edema, manifested by a shrunken ovary
and a swollen bursa were detected during the acute
phase, 24 hours following doxorubicin treatment. The
trend of decline persisted also one month after treat-
ment (Fig 3B), consistent with the relative reduction in
ovary weight but inconsistent with the partial recovery
in ovulation rate reported in a former section.
Induction of follicular apoptosis by doxorubicin
Ovaries of female mice injected with doxorubicin were
excised, fixed and sectioned at various time points after
exposure to the agent. Occurrence of DNA fragmenta-
tion and apoptosis in ovarian follicles were assessed in
Figure 1 Changes in ovarian weight induced by doxorubicin.
Ovaries of female mice injected with doxorubicin were excised,
weighed one week or one month after injection and compared
with those of saline-injected control mice. Bars represent weight
(mean ± SEM) of ovaries, (*)-significantly different from control value
(P < 0.05); N = number of ovaries.
Figure 2 Ovulation rate following doxorubicin treatment.
Female mice were injected with doxorubicin or with saline.
Ovulation was induced by injecting the mice with 5 IU hCG 48
hours after administration of 10 IU of PMSG. The mice were
sacrificed 16-17 hours after hCG administration at a time coinciding
with either 48 hours, one week or one month after the doxorubicin
or saline injections. The number of ovulated oocytes was recorded.
Bars represent percent of ovulated control oocytes (mean ± SEM),
(*)-significantly different from control value (P < 0.05); N = number
of mice.
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and active caspase-3 assays, respectively, 12 or 24 hours
post treatment. Fluorescence microscopy revealed posi-
tive TUNEL reaction in secondary and pre-antral folli-
cles, but most prominently in antral follicles. The
reaction signal was weakly evident 12 hours after doxor-
ubicin treatment, mostly in the granulosa compartment,
enhanced and shifted towards the oocyte 24 hours post
treatment. The primordial follicles did not display stain-
ing in this assay while primary follicles were faintly
stained (Fig 4A).
Active caspase-3 was clearly manifested in secondary
follicles, pre-antral and antral follicles 12 hours follow-
ing doxorubicin treatment, corresponding with the
location of TUNEL staining, although caspase 3 staining
was evident earlier than the TUNEL reaction (Fig 4B).
The effect of doxorubicin on the follicular population
within the ovary
Bouin-fixed ovaries, one month post treatment, were
sectioned and stained by Hematoxylin-Eosin. The ovar-
ian follicles were counted and categorized according to
their developmental stage. T h ep o p u l a t i o ns i z eo fe a c h
Figure 3 The effect of doxorubicin on the size of ovaries.T h e
ovaries of anaesthetized mice injected with doxorubicin or with
saline were imaged with a high-resolution coronal T2-weighted MRI
24 hours and one month post injection. (A) A relative decline in
ovaries size was observed already 24 hours post treatment and
persisted also one month post treatment. Bars represent percent of
control (mean ± SEM), (*)-significantly different from control value (P
< 0.05); N = number of mice. (B) Representative images of ovaries
from saline-injected (a) and doxorubicin-injected (b) mice at one
month post treatment.
Figure 4 Doxorubicin induced ovarian apoptosis. Confocal
micrographs of ovaries excised from doxorubicin or saline-injected
mice, 12 or 24 hours after treatment. Ovaries of saline-treated mice
(A, A’A”). Ovaries of doxorubicin-treated mice 12 hours (B, B’B”)o r2 4
hours (C, C’C”) after treatment. Magnification: ×10 (A-C), ×20 (A’-C’),
×63 (A"-C”). (A) TUNNEL staining (green), (B) caspase-3 staining (red).
Blue staining represents DNA labeling by Heochst 32242.
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from doxorubicin and saline injected mice. The size of
secondary follicles population, one month after doxoru-
bicin administration, was significantly reduced compared
to the control group (p = 0.03; Fig 5). The population of
primary, primordial and antral follicles also decreased in
size one month after doxorubicin treatment, thugh not
statistically significant (p = 0.06 and 0.08, respectively).
Furthermore, the ovarian cortex of doxorubicin-trea-
ted mice appeared more vascular, with thickening and
hyalinization of the vessels wall. The vascular changes
were evident in sections of ovaries excised one month
following doxorubicin administration (data not shown)
Discussion
In this study we explored the possible patterns of apop-
totic processes initiated within the mouse ovary follow-
ing exposure to the widely used chemotherapeutic
agent, doxorubicin. The dose employed was equipotent
to that used in humans, specifically in breast cancer
patients. The observation, depicted by in vivo MRI ima-
ging, of a decrease in ovarian size occurring after doxor-
ubicin administration was further validated by a similar
effect on ovarian weight, though the mean weight of
ovaries excised from doxorubicin-treated mice at various
post-treatment time points might also reflect inter-mice
variability. This variability was minimized by repeatedly
imaging with MRI the same treated individuals at the
same post-treatment intervals. An acute effect, observed
by MRI within the first 24 hours post treatment, indi-
cated a marked peri-ovarian edema that may represent
actual ovary shrinkage, caused by a shift of fluids from
the ovarian tissue to the surrounding bursal sac (or peri-
toneal space in human). This phenomenon may resem-
ble the radiological phenomenon referred to as ‘Page
kidney’, where an external compression of the kidney
causes renal hypoperfusion and ischemia [17]. Some stu-
dies suggested that this pathogenesis involves “parenchy-
mal scarring” of the kidney [18]. Though we suggest
that our observation of doxorubicin-induced impaired
ovarian size and weight may involve an analogous
mechanism of an acute ovarian insult due to ischemia
(which may be followed by parenchymal fibrosis), the
matter should be further explored. The effect on ovary
size persisted even one month post treatment. The “one
month” time point was chosen since it correlates to 6-7
menstrual cycles (6-7 months), the estimated number of
cycles required for human follicular growth and matura-
tion [19]. Despite the increased impairment in ovary
size over time, the decrease in ovulation rate following
exposure to doxorubicin was partially reversed. How-
ever, as formerly reported, the reproductive performance
of cyclophosphamide treated female mice, expressed by
ovulation; mating and pregnancy rate was not compro-
mised compared to control mice, although most of the
population of primordial follicles had been destroyed.
Nonetheless, a considerable reduction in the number of
pregnancy sacs was observed in females mated one
week after cyclophosphamide treatment, which may sug-
gest that mature follicles are more sensitive to che-
motherapy-induced damage [9]. In our study
doxorubicin injected mice presented compromised ovu-
lation rates and hence also reduced blastocysts count in
mated mice of this group. Furthermore, we observed
many atretic antral follicles within the ovaries at 24
hours and one month after doxorubicin administration,
which correlated with the significant reduction in ovula-
tion rate. Nevertheless, oocytes ovulated by doxorubicin-
treated mice revealed neither morphological nor chro-
mosomal changes compared with oocytes ovulated by
control mice (data not shown). Hyperstimulating the
ovaries with gondaotropins recruits gonadotropins-
Figure 5 Depletion of ovarian follicles reservoir by doxorubicin. The number of ovarian follicles (mean ± SEM) at various developmental
stages, one month after injection of doxorubicin or saline. Bars represent mean ± SEM, (*)-significantly different from control value (P < 0.05).
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recovery of ovulation rate depicted one month after
doxorubicin administration correlates with the physiolo-
gical time-span required for the mouse primary follicles
to mature.
In an attempt to characterize the apoptotic effect of
doxorubicin on the ovary, we were able to detect apop-
tosis in histological sections of mice ovaries by depicting
caspase-3 activity, as soon as 12 hours following expo-
sure to the agent. TUNEL staining was noticeable only
when the apoptotic end-products accumulated, 12-24
hours following doxorubicin administration. Further his-
tological changes, induced by doxorubicin in the stromal
portion of the ovary were observed. It had formerly been
documented that ovarian histological biopsies from
women who had received various chemotherapeutic
regimens, exhibited altered ovarian stromal function as
reflected by lower in vitro production of estradiol,
regardless the presence of an alkylating agent in the
chemotherapeutic regimen and irrespective of the mag-
nitude of germ cell damage [20]. We observed fibrosis
of the cortical vessels of ovaries of doxorubicin treated
but not of control mice. It has been previously shown
that doxorubicin at submicromolar concentrations
induces in endothelial cells apoptosis that is mediated
presumably by formation of oxidative free radicals and
causes impaired endothelial function [21-23]. Further-
more, cortical fibrosis had already been described in his-
tological sections of ovarian biopsies taken from women
receiving chemotherapy [7]. The loss of premature folli-
cles, as well as the perivascular and parenchymal
changes in ovaries of mice treated with doxorubicin in
vivo, correlate with the histological modifications
demonstrated in human ovaries following administration
of other chemotherapeutic agents such as cyclophspha-
mide and cisplatin [5]. These studies hypothesized a
combined mechanism of neovascularization and ovarian
tissue scarring with a direct toxic effect on the primor-
dial follicles. Mice primordial follicles are destroyed fol-
lowing administration of the chemotherapeutic drug
cyclophosphamide [9]. We had presented quantitative
evidence that in vivo doxorubicin treatment results in a
significant loss of follicular reserve within mice ovaries,
mostly secondary follicles, and a nearly statistical signifi-
cant trend of decline in the number of primordial and
primary follicles. Populations of all follicles were
damaged, significantly the secondary follicles. The pri-
mordial follicles presented a trend consistent with pub-
lished data of other chemotherapies. The pronounced
depletion of the follicular population was observed one
month following exposure to the agent (equivalent to 6-
7 months in human). As mentioned, there is former evi-
dence in the literature for loss of primordial follicles in
rodents treated with alkylating agents [9] as well as in
women treated with alkylating agents-based protocols
[13,20]. According to previous studies and daily practice,
the ovarian reproductive potential of chemotherapy sur-
vivors is assessed mainly by documenting menstrual
activity or specific hormonal markers in serum. Since
menstruation does not accurately reflect the fertility
state [22,24,25], assessing the population of primordial
follicles in the ovary may serve as a better indicator.
The follicular reserve within the ovaries consists
mainly of quiescent primordial follicles developed during
fetal life. A tremendous number of primordial follicles
will be annihilated, before or shortly after birth and
throughout postnatal life, by a physiological pro-
grammed cell death process (i.e., apoptosis(; [26]. Cas-
pases, cysteine proteases synthesized as pro-enzymes
and activated by autocatalytic cleavage or by other pro-
teases, are considered as key effectors during the apop-
totic cascade. It is well established that caspase-3 plays a
pivotal role in the execution of apoptosis and is predo-
minantly localized in granulosa cells of atretic follicles.
It has been suggested that caspase-3 might be involved
in the physiological follicular atresia within ovaries
[27,28]. This physiological cellular machinery may pre-
dispose the follicles to apoptosis induced by exogenous
signals, such as chemotherapeutic agents. This trait may
correlate with the higher rate of premature ovarian fail-
ure observed in women following chemotherapy treat-
ment [1]. Hence, due to the decrease in primordial
follicles pool size throughout physiological aging, the
rate of ovarian failure observed in older women treated
with chemotherapy is higher than in younger women
[1,29].
Since the effect of doxorubicin was evident both
microscopically at both cell and organ levels, we suggest
a whole-organ effect of the agent. In vivo imaging of the
ovaries served as a tool for tracking down the whole
organ pattern of the gonadotoxic effect of doxorubicin
and may be used as a platform for future investigation
of agents needed to shield the ovaries from chemother-
apy peril.
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